Biotech
-
Bluebird, short on cash, takes on $175M in debt financing
The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits…
Read More » -
FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma
A majority of experts believed that the factors that may have led to an increased risk of early death in…
Read More » -
Madrigal wins FDA approval of first drug for MASH
Rezdiffra’s clearance is a turning point in the fight against the liver disease. But its sales potential is unclear, and…
Read More » -
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
Allogene’s partnership with Arbor is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas…
Read More » -
FDA clears use of Novo’s obesity drug to protect heart health
The approval makes Novo’s Wegovy the first weight-loss drug with such a claim on its prescribing information, which could have…
Read More » -
Why Cigna is capping cost increases for pricey obesity drugs
The the first of its kind move comes as pharmacy benefit managers continue to try to prove their value to…
Read More » -
Sionna raises another $182M to challenge Vertex in cystic fibrosis
Incubated by RA Capital and backed by a wide array of investors, the startup is developing drugs that work differently…
Read More » -
Akero strengthens MASH drug’s case with new study data
The updated results show that responses to the drug, which is currently in late-stage testing, deepened with time, helping the…
Read More » -
FogPharma pulls in $145M to support cancer drug research
The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an…
Read More » -
Incannex says psilocybin therapy lowered anxiety in small study
Shares of the Australian biotech rocketed up about 55% after the company announced results from a mid-stage study in generalized…
Read More »